Chief Development Officer
Anne-Marie Li-Kwai-Cheung joined Wave in February 2022 as Senior Vice President, Regulatory Affairs, Compliance and Policy and was promoted to Chief Development Officer in September 2022. In her current role, Anne-Marie oversees all preclinical and clinical drug development activities at Wave.
Anne-Marie was previously at Roche (Basel, Switzerland), where she started in Global Regulatory Affairs and went on to hold leadership positions of increasing responsibility in global drug development and global program leadership within the neurology and rare disease therapeutic areas. She served as Life Cycle Leader for tominersen in Huntington’s disease, guiding the Phase 3 program and other late-stage development activities, including responsibility for commercial activity, reimbursement, medical affairs, development and manufacturing and supply. In addition, she led the filing and development team at Roche through the global launch of Ocrevus for multiple sclerosis. Her career also reflects her keen interest in personalized medicines, as she led a team focused on the development of novel digital outcome measures for neurological diseases, and software as a medical device (SaMD) to enable physicians and patients to better understand and manage disease progression. Prior to her work at Roche, Anne-Marie worked for Genzyme, leading regulatory teams in regulatory filings and a filing team for an advanced therapy during a period of significant legislative changes. With more than 20 years’ experience across major pharmaceutical companies, including GlaxoSmithKline and Wyeth, Anne-Marie has broad experience with the execution of strategic development and regulatory plans that deliver timely and meaningful therapies for patients.
Anne-Marie earned a master’s degree in medicinal chemistry from the University of Salford and is a member of RAPS (Regulatory Affairs Professionals Society) and TOPRA (The Organisation for Professionals in Regulatory Affairs).